Results 91 to 100 of about 1,935,200 (187)
Atherosclerosis: From Pathogenesis to Therapeutic Interventions
MedComm, Volume 7, Issue 11, November 2026.The diagram outlines the core mechanisms driving atherosclerosis, including endothelial dysfunction, inflammatory responses, phenotypic switching of smooth muscle cells, and the gut–vascular axis. It also presents the corresponding therapeutic approaches now under development, such as gene therapies, immunotherapies, and nanotechnology platforms ...
Enge Zhou +9 more
wiley +1 more source
Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent
, 2008 Jonathan Bridges, Donald CutlipBeth Israel Deaconess Medical Center, Boston, Massachusetts, USAAbstract: Coronary artery disease remains one of the leading causes of death in the United States.
Jonathan Bridges, Donald Cutlip
core
Nano Select, Volume 7, Issue 11, November 2026.The influence of SPION mass fraction, pH/medium, initial coating mass, and carrier material on the degradation of PLA‐SPION markers for medical instruments is investigated. Especially, the pH and the surrounding medium strongly influence the degradation kinetics.
Patrick Naoki Elfers +13 more
wiley +1 more source
Small, Volume 22, Issue 61, 2 November 2026.A multifunctional 3D‐printed polymer–ZrO2 scaffold is developed to provide intrinsic radiopacity, photothermal responsiveness, and surface bioactivity. Reinforcement with ZrO2 enables real‐time x‐ray visibility and mechanical robustness, while a polydopamine coating facilitates near‐infrared‐triggered drug release and modulates cell migration, thereby ...
Sumin Kang +10 more
wiley +1 more source
Coating stent materials with polyhedral oligomeric silsesquioxane-poly(carbonateurea)urethane nanocomposites [PDF]
, 2009 The long-term efficacy of coronary or peripheral stenting is limited by in-stent restenosis (ISR), which occurs in 15 to 30% of patients and is attributed primarily to neointimal hyperplasia.
Bakhshi, R.
core
Stent Fracture after Everolimus-Eluting Stent Implantation
Cardiology Research and Practice, 2011 Compared with bare-metal stents, drug-eluting stents (DES) have greatly reduced the risk of in-stent restenosis (ISR) by inhibiting neointimal growth. Nevertheless, DES are still prone to device failure, which may lead to cardiac events.
Ali S. Almasood +4 more
doaj +1 more source
Journal of Diabetes Investigation, Volume 17, Issue 11, Page 1986-1996, November 2026.Among patients with type 2 diabetes undergoing percutaneous coronary intervention, thiazolidinedione use was independently associated with a significantly reduced risk of a composite of myocardial infarction, stroke, and all‐cause death, notably without an increased risk of admission for heart failure. ABSTRACT Background Thiazolidinediones (TZD) are a
Jinkwon Kim +5 more
wiley +1 more source
, 2007 Alaide Chieffo, Tiziana Claudia Aranzulla, Antonio ColomboInterventional Cardiology Unit, San Raffaele Scientific Institute, Milan, ItalyAbstract: Coronary bifurcations represent a challenging lesions subset and account for up to 15% of all current PCI ...
Alaide Chieffo +2 more
core
MoleculesOncology and cardiology use paclitaxel, a powerful cell-division inhibitor. Paclitaxel-eluting coated metal stents in oncology prevent tumor growth by modulating proliferation, apoptosis, and angiogenesis.
Andreea Crețeanu +5 more
doaj +1 more source
Drug-eluting stents in the management of peripheral arterial disease
, 2008 Marc Bosiers1, Catherine Cagiannos1, Koen Deloose1, Jürgen Verbist2, Patrick Peeters21Department of Vascular Surgery, AZ St-Blasius, Dendermonde, Belgium; 2Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden ...
Koen Deloose +4 more
core